Cancer Prevention News and Research

RSS

Molecular analysis of COVID-19's second wave shows mutant viruses linked to rapid spread

Molecular analysis of COVID-19's powerful second wave in Houston – from May 12 to July 7 – shows a mutated virus strain linked to higher transmission and infection rates than the coronavirus strains that caused Houston's first wave.

24 Sep 2020

Lack of considerations in cumulative effect of food chemicals could have contributed to increased chronic diseases

Today, a group of health, environmental, and consumer organizations challenged the Food and Drug Administration's (FDA) practice of not accounting for the cumulative health effect of chemicals in the diet when allowing new chemicals in food.

24 Sep 2020

NAU researcher awarded $3.75 million NCI grant to build cancer research software

Greg Caporaso, director of the Center for Applied Microbiome Science, part of the Pathogen and Microbiome Institute at Northern Arizona University, has been awarded a $3.75 million grant by the National Cancer Institute to build software capable of analyzing and archiving data focused on the interplay between the human microbiome (the trillions of microorganisms living in and on the human body) and diverse types of cancer.

22 Sep 2020

Sotorasib phase 1 trial shows encouraging anti-cancer activity in lung, colorectal cancers

A phase 1 clinical trial of sotorasib (AMG 510) in patients with heavily pretreated advanced solid tumors shows encouraging anti-cancer activity, especially in lung and colorectal cancers, reports a new study led by City of Hope and other renowned comprehensive cancer centers.

22 Sep 2020

Targeted therapy improves disease-free survival in patients with early-stage NSCLC

According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.

21 Sep 2020

KRASG12C inhibitor sotorasib shows durable clinical benefits for solid cancers

In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefits.

21 Sep 2020

Adding abemaciclib to hormonal therapy reduces recurrence in patients with HR+ HER2- early breast cancer

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020.

21 Sep 2020

Study finds wide variation in levels and anti-tumor effectiveness of a common cancer drug

When used to manage infections, the drug itraconazole is generally given at a single, fixed dose to all patients.

17 Sep 2020

Study highlights the importance of considering strain differences when designing therapies

Interferon (IFN) responses are one of the first defenses the body mounts against viral infections, and research has shown that it plays a role controlling viral replication.

11 Sep 2020

Study shows how mutations in DNA packaging machines can drive cancer development

Like wrenches made of Legos, SWI/SNF chromatin remodeling complexes tighten or loosen DNA in our cells to control how genes are turned on and made into proteins.

7 Sep 2020

Statistical model uses genomic data to predict a person's risk for esophageal cancer

7 Sep 2020

Suppressing tumor's growth and spread from the inside

A new technology that allows researchers to peer inside malignant tumors shows that two experimental drugs can normalize aberrant blood vessels, oxygenation, and other aspects of the tumor microenvironment in non-small cell lung cancer, helping to suppress the tumor's growth and spread, UT Southwestern researchers report.

3 Sep 2020

Improved type of PROTAC enhances intracellular accumulation and protein knockdown

Cancer therapies sometimes involve drugs that mediate the breakdown of specific intracellular proteins that participate in cancer formation and proliferation.

27 Aug 2020

New surgical approach is highly acceptable among women with ovarian cancer risk

A new two-stage surgical approach for cancer prevention is highly acceptable among premenopausal women at high risk of ovarian cancer, according to research led by Queen Mary University of London.

24 Aug 2020

New discovery about STING protein could lead to improved cancer immunotherapies

The immune protein STING has long been noted for helping protect against viruses and tumors by signaling a well-known immune molecule.

24 Aug 2020

Study identifies a novel regulatory pathway in bladder cancer

Researchers from Johns Hopkins University in collaboration with Insilico Medicine announce the publication of a new research paper titled "GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma" in Science Signaling.

20 Aug 2020

Study may lead to new targeted therapies that inhibit the spread of cancer

For decades, physicians have known that many kinds of cancer cells often spread first to lymph nodes before traveling to distant organs through the bloodstream.

20 Aug 2020

Shielding stem cells with novel biomaterial can reduce heart attack damage

Bioengineers and surgeons from Rice University and Baylor College of Medicine (BCM) have shown that shielding stem cells with a novel biomaterial improves the cells' ability to heal heart injuries caused by heart attacks.

18 Aug 2020

Gene editing approach removes oral herpes

Infectious disease researchers at Fred Hutchinson Cancer Research Center have used a gene editing approach to remove latent herpes simplex virus 1, or HSV-1, also known as oral herpes.

18 Aug 2020

Study: Drinking honeysuckle decoction accelerates the negative conversion of COVID-19 patients

In a new study in Cell Discovery, Chen-Yu Zhang's group at Nanjing University and two other groups from Wuhan Institute of Virology and the Second Hospital of Nanjing present a novel finding that absorbed miRNA MIR2911 in honeysuckle decoction (HD) can directly target SARS-CoV-2 genes and inhibit viral replication. Drinking of HD accelerate the negative conversion of COVID-19 patients.

7 Aug 2020

Cancer Prevention News and Research

Molecular analysis of COVID-19's second wave shows mutant viruses linked to rapid spread

Lack of considerations in cumulative effect of food chemicals could have contributed to increased chronic diseases

NAU researcher awarded $3.75 million NCI grant to build cancer research software

Sotorasib phase 1 trial shows encouraging anti-cancer activity in lung, colorectal cancers

Targeted therapy improves disease-free survival in patients with early-stage NSCLC

KRASG12C inhibitor sotorasib shows durable clinical benefits for solid cancers

Adding abemaciclib to hormonal therapy reduces recurrence in patients with HR+ HER2- early breast cancer

Study finds wide variation in levels and anti-tumor effectiveness of a common cancer drug

Study highlights the importance of considering strain differences when designing therapies

Study shows how mutations in DNA packaging machines can drive cancer development

Statistical model uses genomic data to predict a person's risk for esophageal cancer

Suppressing tumor's growth and spread from the inside

Improved type of PROTAC enhances intracellular accumulation and protein knockdown

New surgical approach is highly acceptable among women with ovarian cancer risk

New discovery about STING protein could lead to improved cancer immunotherapies

Study identifies a novel regulatory pathway in bladder cancer

Study may lead to new targeted therapies that inhibit the spread of cancer

Shielding stem cells with novel biomaterial can reduce heart attack damage

Gene editing approach removes oral herpes

Study: Drinking honeysuckle decoction accelerates the negative conversion of COVID-19 patients

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News